To the Editor,

We read the published article "Visit-to-visit variability in low-density lipoprotein cholesterol is associated with adverse events in non-obstructive coronary artery disease. Anatol J Cardiol 2019; 22: 117-24" with great interest ([@ref1]). Gu et al. ([@ref1]) concluded that "Among the patients with non-obstructive CAD, a higher visit-to-visit LDL-C variability is associated with increasing all-cause mortality or composite endpoints during the long-term follow-up". We would like to share our ideas on this report. An important consideration is the quality control principle in LDL-C determination in laboratory medicine. For any clinical profile test in laboratory, variability in test results can naturally occur. The clinical laboratory has to control for with-in day and between-day variation, which is related to daily environmental conditions ([@ref2]). The variation is not related to any pathophysiological process in the patient but to the analytic factors in the laboratory. LDL-C determination by different types of analysis in the same laboratory can simply result in variation of LDL-C results. Thus, Gu et al. ([@ref1]) have to control for the described factors. LDL-C determination has to be performed using the same technique and analyzer. Different LDL-C assays can have different diagnostic properties and result in possible misinterpretation of results ([@ref3]).

Nevertheless, with the described control, the between-day variation can still occur.
